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To the Editor: Cryptococcal meningitis is a life-threatening
mycotic infection common in HIV-positive patients
Amphotericin B and fluconazole are two medications used to
treat cryptococcosis in South Africa.1 Lifelong daily fluconazole
prophylaxis after resolution of the primary infection has
proved to be effective in preventing relapse.2
Case report
A 40-year-old HIV-positive man was admitted to Cecilia
Makiwane Hospital in December 2001 with a history of severe
headache, photophobia and fever. Indian ink staining of
cerebrospinal fluid (CSF) revealed yeast cells with 3 - 5
budding forms per high-power field. A diagnosis of
cryptococcal meningitis was made and the patient was started
on amphotericin B. He reacted to this almost immediately, and
was observed to have a spiking temperature, tachycardia, and
dizziness. He was changed to oral fluconazole 400 mg daily. He
improved and was continued on 400 mg of fluconazole for 2
months, and then 200 mg daily.
At subsequent monthly follow-up visits the patient  was
well. He attended all outpatient appointments, and stated that
he was taking treatments as prescribed.
In July 2002 he was readmitted with signs and symptoms of
meningitis. CSF examination again revealed budding yeast
cells. The patient repeatedly refused the option of amphotericin
B because of his previous reaction to this medication. Oral
fluconazole was increased to 800 mg per day. The patient’s
condition continued to deteriorate and he died 2 weeks after
admission. Numerous budding forms were still seen on a CSF
specimen taken days before his death, and the CSF was
cultured.
Cryptococcus neoformans was grown on culture in our
laboratory, and the organism was found to be resistant to
fluconazole. The organism was sent for minimum inhibitory
concentration (MIC) testing but the specimen went astray.
Comment
The prevalence of fluconazole-resistant C. neoformans in South
Africa is either unknown or poorly publicised. Depending on
the resources and protocols available in different centres,
treatment may be initiated with amphotericin B, fluconazole, or
both.3 However, the fluconazole donation by Pfizer in 2001 has
lead to more widespread use of this azole as the mainstay of
cryptococcosis therapy. Mortality in Zambian AIDS patients
with cryptococcal meningitis has been shown to be 100% at 6
months, with or without fluconazole treatment 4 (median
survival with fluconazole 19 days). In patients showing no
improvement on fluconazole therapy, culture of CSF, although
currently not routinely done, may aid in quantifying the
problem of resistant C. neoformans in South Africa. Newer
azoles with promising activity against C. neoformans may help
to address this problem in the future, but a case can be made
for a national review of resistance patterns. If such information
already exists, it would be of benefit to caregivers if it were
made public.
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